ZA933023B - The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds. - Google Patents
The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds.Info
- Publication number
- ZA933023B ZA933023B ZA933023A ZA933023A ZA933023B ZA 933023 B ZA933023 B ZA 933023B ZA 933023 A ZA933023 A ZA 933023A ZA 933023 A ZA933023 A ZA 933023A ZA 933023 B ZA933023 B ZA 933023B
- Authority
- ZA
- South Africa
- Prior art keywords
- inflammations
- wounds
- inhibitors
- treatment
- plasminogen activators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4214215A DE4214215A1 (en) | 1992-04-30 | 1992-04-30 | USE OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATING INFLAMMATION |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA933023B true ZA933023B (en) | 1994-10-31 |
Family
ID=6457814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA933023A ZA933023B (en) | 1992-04-30 | 1993-04-29 | The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0567816A1 (en) |
JP (1) | JPH069425A (en) |
KR (1) | KR930021179A (en) |
CN (1) | CN1080873A (en) |
AU (1) | AU3822993A (en) |
CA (1) | CA2095207A1 (en) |
CZ (1) | CZ76893A3 (en) |
DE (1) | DE4214215A1 (en) |
HU (1) | HUT65755A (en) |
IL (1) | IL105521A0 (en) |
MX (1) | MX9302519A (en) |
NO (1) | NO931561L (en) |
PL (1) | PL298748A1 (en) |
SK (1) | SK41593A3 (en) |
UY (1) | UY23572A1 (en) |
ZA (1) | ZA933023B (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5468505A (en) * | 1992-02-28 | 1995-11-21 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
GB2271507A (en) * | 1992-09-04 | 1994-04-20 | Summit Technology Ireland Bv | Compositions containing plasmin activity inhibitors |
ATE339975T1 (en) * | 1993-07-19 | 2006-10-15 | Angiotech Pharm Inc | ANTI-ANGIOGENIC STENT AND METHOD FOR THE PRODUCTION THEREOF |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6558798B2 (en) | 1995-02-22 | 2003-05-06 | Scimed Life Systems, Inc. | Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity |
US5939525A (en) * | 1995-03-27 | 1999-08-17 | Viron Therapeutics, Inc. | Methods of treating inflammation and compositions therefor |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US20040254635A1 (en) | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
KR20010042402A (en) * | 1998-04-01 | 2001-05-25 | 로잘란드 앤 칼도르 | Use of protease inhibitors for treating skin wounds |
US6293967B1 (en) | 1998-10-29 | 2001-09-25 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US6120847A (en) * | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
MXPA01011025A (en) | 1999-04-29 | 2002-11-07 | Ista Pharmaceuticals Inc | Biochemical methods that eliminate corneal scars, opacification and haze. |
US6156373A (en) | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
JP3690720B2 (en) | 1999-09-14 | 2005-08-31 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Client server system, object pooling method, and storage medium |
ATE297217T1 (en) | 1999-10-27 | 2005-06-15 | Alexandra Lucas | COMPOSITION FOR PREVENTING AND TREATING TRANSPLANT REJECTION |
JP2001247458A (en) * | 2000-03-08 | 2001-09-11 | Hamari Chemicals Ltd | Therapeutic agent for diabetes comprising zinc tranexmate compound |
AU2001291579B2 (en) | 2000-09-29 | 2006-08-31 | Viron Therapeutics Inc. | Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions |
US6764507B2 (en) | 2000-10-16 | 2004-07-20 | Conor Medsystems, Inc. | Expandable medical device with improved spatial distribution |
EP1582180B1 (en) | 2000-10-16 | 2008-02-27 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
AT500019B1 (en) * | 2001-06-27 | 2007-06-15 | Inst Gefaessbiologie Und Throm | USE IN VITRO OF THE TRANSCRIPTION FACTOR NAK-1 OR NAK-1 REGULATED GENES FOR THE DIAGNOSIS OF INFLAMMATORY AND MALIGNIC DISEASES |
GB0126389D0 (en) * | 2001-11-02 | 2002-01-02 | Pfizer Ltd | Wafer |
US7785653B2 (en) | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
WO2009093119A2 (en) * | 2008-01-21 | 2009-07-30 | Med Discovery S.A. | Use of serine protease inhibitors in the treatment of skin diseases |
TWI763960B (en) * | 2017-12-15 | 2022-05-11 | 大陸商深圳瑞健生命科學研究院有限公司 | Method and medicine for preventing or treating osteoarthritis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3829523A1 (en) * | 1988-08-31 | 1990-03-01 | Behringwerke Ag | USE OF PLASMINOGEN ACTIVATOR INHIBITOR (PAI-2) FOR IMMUNE SUPPRESSION |
US5444153A (en) * | 1989-12-20 | 1995-08-22 | Biotech Australia Pty Limited | Variants of PAI-2 |
EP0451130A3 (en) * | 1990-04-05 | 1992-08-05 | Baltimore Biotech, Inc. | Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization |
-
1992
- 1992-04-30 DE DE4214215A patent/DE4214215A1/en not_active Withdrawn
-
1993
- 1993-04-08 EP EP19930105801 patent/EP0567816A1/en not_active Withdrawn
- 1993-04-27 UY UY23572A patent/UY23572A1/en unknown
- 1993-04-27 IL IL105521A patent/IL105521A0/en unknown
- 1993-04-28 JP JP5101636A patent/JPH069425A/en active Pending
- 1993-04-28 CZ CZ93768A patent/CZ76893A3/en unknown
- 1993-04-28 SK SK415-93A patent/SK41593A3/en unknown
- 1993-04-28 KR KR1019930007154A patent/KR930021179A/en not_active Application Discontinuation
- 1993-04-29 PL PL29874893A patent/PL298748A1/en unknown
- 1993-04-29 NO NO93931561A patent/NO931561L/en unknown
- 1993-04-29 MX MX9302519A patent/MX9302519A/en unknown
- 1993-04-29 ZA ZA933023A patent/ZA933023B/en unknown
- 1993-04-29 AU AU38229/93A patent/AU3822993A/en not_active Abandoned
- 1993-04-29 CN CN93105253A patent/CN1080873A/en active Pending
- 1993-04-29 CA CA002095207A patent/CA2095207A1/en not_active Abandoned
- 1993-04-30 HU HU9301272A patent/HUT65755A/en unknown
Also Published As
Publication number | Publication date |
---|---|
UY23572A1 (en) | 1993-05-04 |
CN1080873A (en) | 1994-01-19 |
DE4214215A1 (en) | 1993-11-04 |
EP0567816A1 (en) | 1993-11-03 |
AU3822993A (en) | 1993-11-04 |
MX9302519A (en) | 1993-10-01 |
JPH069425A (en) | 1994-01-18 |
HU9301272D0 (en) | 1993-07-28 |
NO931561L (en) | 1993-11-01 |
HUT65755A (en) | 1994-07-28 |
PL298748A1 (en) | 1993-12-27 |
CZ76893A3 (en) | 1994-01-19 |
NO931561D0 (en) | 1993-04-29 |
CA2095207A1 (en) | 1993-10-31 |
IL105521A0 (en) | 1993-08-18 |
KR930021179A (en) | 1993-11-22 |
SK41593A3 (en) | 1993-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA933023B (en) | The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds. | |
AU5590596A (en) | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration | |
AU6276194A (en) | Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer | |
AU2956492A (en) | Antibacterial agent and treatment of article therewith | |
EP0622063A3 (en) | Disposable absorbent articles and methods of making same. | |
AU4859793A (en) | Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation | |
EP0594410A3 (en) | Treatment of rubber articles. | |
AU3959193A (en) | Heterocyclic compounds and their use in the treatment of type II-diabetes | |
AU3107795A (en) | Inhibitors of the benzamidine type | |
AU4069095A (en) | Medicaments for the treatment of restenosis and arterial sclerosis | |
AU3099997A (en) | The use of tcet in the prophylaxis and treatment of allergies | |
ZA935575B (en) | Therapeutic agent and its use. | |
IL108098A0 (en) | Inhibitors of hiv protease useful for the treatment of aids | |
IL105973A0 (en) | Inhibitors of hiv protease useful for the treatment of aids | |
EP0577023A3 (en) | Angiotensin-ii receptor-antagonists for the treatment of arrhythmices | |
EP0674707A4 (en) | Compounds and methods for the treatment of leukemias. | |
GB9409336D0 (en) | Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis | |
GB2267089B (en) | Cycloheptimidazole derivatives,method of manufacturing the same and therapeutic agents containing these compounds | |
AU1870292A (en) | Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity | |
AU4585993A (en) | Use of angiotensin ii antagonists for the treatment of hyperlipidaeme | |
AU7688998A (en) | Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema | |
GB9317943D0 (en) | Treatment of laminitis | |
AU4825993A (en) | New compounds for use in the treatment of cancer | |
AU612562B2 (en) | A composition comprising a plasmin inhibitor and a plasminogen activator for the treatment of thrombosis | |
ZA929143B (en) | Agents for use in the prophylaxis and therapy of fungal infections. |